Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil

Journal of Laryngology and Otology

Volumn 124, Issue 10, 2010, Pages 1056-1060

  Araujo Melo, M H ^a   Meneses, A M ^d   Schubach, A O ^a   Moreira, J S ^a   Conceicao Silva F ^b   Salgueiro, M M ^a   Pimentel, M I F ^a   Araujo Silva M ^a   Oliveira, R V C ^c   Carmo, C N ^b   Valete Rosalino, C M ^a  

^a Evandro Chagas Clinical Research Institute   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Laboratory of Clinical Epidemiology   (Brazil)

^d Central Hospital of Rio de Janeiro   (Brazil)

Author keywords

Dizziness; Leishmaniasis; Meglumine Antimoniate; Ototoxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; MEGLUMINE ANTIMONATE; TRIACYLGLYCEROL LIPASE; UREA;

ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAZIL; CHILD; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DIZZINESS; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SCHOOL CHILD; SKIN LEISHMANIASIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA BLOOD LEVEL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIPROTOZOAL AGENTS; BRAZIL; CHILD; CHILD, PRESCHOOL; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEISHMANIASIS, MUCOCUTANEOUS; LIPASE; MALE; MEGLUMINE; MIDDLE AGED; ODDS RATIO; ORGANOMETALLIC COMPOUNDS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 78649938072     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215110001325     Document Type: Article

References (41)

1. Goodwin LG. Pentostam (sodium stibogluconate); a 50- year personal reminiscence [Historical Article]. Trans R Soc Trop Med Hyg 1995;89:339-41
2. Di Lella F, Vicenti V, Zennaro D, Afeltra A, Baldi A, Giordano D et al. Mucocutaneous leishmaniasis: Report of a case with massive involvement of nasal, pharyngeal and laryngeal mucosa. Int J Oral Maxillofac Surg 2006;35:870-2
3. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC. Mucosal leishmaniasis: Current scenario and prospects for treatment. Acta Trop 2008;105:1-9
4. Vianna G. About the treatment of cutaneous leishmaniasis [in Portuguese]. An. Paul Med Cir 1914;2:167-9
5. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis 1988;10:560-86
6. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46:296-306
7. Azeredo-Coutinho RB, Mendonca SC. An intermittent schedule is better than continuous regimen of antimonial therapy for cutaneous leishmaniasis in the municipality of Rio de Janeiro, Brazil. Rev Soc Bras Med Trop 2002;35: 477-81
8. Azeredo-Coutinho RB, Mendonca SC, Callahan H, Portal AC, Max G. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J Parasitol 2007;93:688-93
9. Ministério da Saúde. Manual Monitoring of Cutaneous Leishmaniasis [in Portuguese]. Brazil: Fundação Nacional de Saúde, 2007
10. Oliveira-Neto MP, Schubach A, Araujo ML, Pirmez C. High and low doses of antimony (Sbv) in American cutaneous leishmaniasis. A five years follow-up study of 15 patients. Mem Inst Oswaldo Cruz 1996;91:207-9
11. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves- Costa SC, Pirmez C. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10 years). Am J Trop Med Hyg 1997;57:651-5
12. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves- Costa SC, Pirmez C. Treatment of American cutaneous leishmaniasis: A comparison between low dosage (5 mg/ kg/day) and high dosage (20 mg/kg/day) antimony regimens. Pathol Biol (Paris) 1997:45:496-9
13. Oliveira-Neto MP, Mattos M, Pirmez C, Fernandes O, Goncalves-Costa SC, Souza CFet al. Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2000;42:321-5
14. Schubach A, Miekeley N, Mortari SR, Moreira JS, Conceição- Silva F, Salgueiro MM et al. Studies on the metabolism of antimony and its species in the treatment of cutaneous leishmaniasis with low doses of antimonials [in Portuguese]. Int Rev Soc Bras Med Trop 2002;35:102-3
15. Schubach AO, Marzochi KBF, Moreira JS, Schubach TMP, Araújo ML, Francesconi-do-Vale AC et al. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate. Int Rev Soc Bras Med Trop 2005;38:213-17
16. Cuce LC, Belda W Jr, Dias MC. Renal changes caused by pentavalent antimonial (Glucantime) hypersensitivity in American tegumentary leishmaniasis. Rev Inst Med Trop Sao Paulo 1990;32:249-51
17. Gasser RA, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90
18. Passos VMA, Barreto SM, Romanha AJ, Krettli AU, Volpini AC, Gontijo CMF et al. Cutaneous leishmaniasis in the metropolitan area of Belo Horizonte: Clinical, laboratory, therapeutic and evolutionary aspects [in Portuguese]. Rev Soc Bras Med Trop 2001;34:5-12
19. Araújo F. Vertigo in the elderly [in Portuguese]. Folha Méd (BR) 1994;108:5-12
20. Grimby A, Rosenhall U. Health-related quality of life and dizziness in old age. Gerontology 1995;41:286-98
21. Ensrud KE, Nevitt MC, Yunis C, Hulley SB, Grimm RH, Cummings SR. Postural hypotension and postural dizziness in elderly women. The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. Arch Intern Med 1992;152:1058-64
22. Colledge NR, Wilson JA, Macintyre CC, MacLennan WJ. The prevalence and characteristics of dizziness in an elderly community. Age Ageing 1994;23:117-20
23. Colledge NR, Barr-Hamilton RM, Lewis SJ, Sellar RJ, Wilson JA. Evaluation of investigations to diagnose the cause of dizziness in elderly people: A community based controlled study. BMJ 1996;313:788-92
24. Tinetti ME, Williams CS, Gill TM. Dizziness among older adults: A possible geriatric syndrome. Ann Intern Med 2000;132:337-44
25. Tinetti ME, Williams CS, Gill TM. Health, functional, and psychological outcomes among older persons with chronic dizziness. J Am Geriatr Soc 2000;48:417-21
26. Lopez-Escamez JA, Lopez-Nevot A, Gamiz MJ, Moreno PM, Bracero F, Castillo J et al. Diagnosis of common causes of vertigo using a structured clinical history [in Spanish]. Acta Otorrinolaringol Esp 2000;51: 25-30
27. Kao AC, Nanda A, Williams CS, Tinetti ME. Validation of dizziness as a possible geriatric syndrome. JAm Geriatr Soc 2001;49:72-5
28. Hearing loss and dizziness in the elderly: Drugs and other associated factors [in Portuguese]. In: Http://bases.bireme. br/cgi-bin/wxislind.exe/iah/ online/ [25 June 2009]
29. Katsarkas A. Dizziness in aging: The clinical experience. Geriatrics 2008;63:18-20
30. Davis LE. Dizziness in elderly men. JAm Geriatr Soc 1994; 42:1184-8
31. Lawson J, Fitzgerald J, Birchall J, Aldren CP, Kenny RA. Diagnosis of geriatric patients with severe dizziness. J Am Geriatr Soc 1999;47:12-7
32. Piker EG, Jacobson GP, McCaslin DL. Psychological comorbidities and their relationship to self-reported handicap in samples of dizzy patients. JAm Acad Audiol 2008;19: 337-47
33. AIDS Table for Grading Severity of Adult Adverse Experiences. In: Http://www.aactg.s-3.com [18 May 2010]
34. Tuon FF, Amato VS. Systematic review of New World cutaneous leishmaniasis: Few points to be applied to Old World leismaniasis. Int J Dermatol 2009;48:201-2
35. Seligmann H, Podoshin L, Ben-Davis J, FradisM, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996;14:192-212
36. Hillen ME, Wagner ML, Sage JI. "Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson Disease. Arch Phys Med Rehabil 1996;77: 710-12
37. Walker EM Jr, Fazekas-May MM, Bowen WR. Nephrotoxic and ototoxic agents. Int Clin Lab Med 1990; 10:323-54
38. Humes H. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci 1999;28:15-18
39. Hyppolito MA, Oliveira JAA, Lessa RM, Rossato M. Amifostine otoprotection against cisplatin ototoxicity: Guinea pig study using distortion product otoacoustic emissions and scanning electron microscopy [in Portuguese]. Rev Bras Otorrinolaringol 2005;71:268-73
40. Cohen N. The patient with dizziness. Update on vestibular disorders [in Portuguese]. Med Clin North America 1991;6: 1283-93
41. Dukes MNG, Aronson JK. Meyler's Side Effects of Drugs, 14th ed. Amsterdam: Elsevier, 2000